-
Mashup Score: 0Sara Bybee on Transgender Patients With Gendered Cancers - 6 month(s) ago
When a transgender patient is diagnosed with a cancer that doesn’t match their gender identity — such as breast, gynecologic, testicular, or prostate cancer — it can have important implications for treatment and outcomes, said authors of a
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Matthew Galsky on Olaparib in Advanced Bladder Cancer Harboring DDR Gene Alterations - 7 month(s) ago
Studies across a range of solid tumor types, including breast, ovarian, and pancreatic cancers, have demonstrated clinical benefit with poly (ADP-ribose) polymerase (PARP) inhibition, particularly in patients harboring alterations in DNA damage response (DDR) genes such as BRCA1/2. A growing body of evidence also suggests that PARP inhibition may be effective in a broader range of DDR alterations.
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
New therapeutic targets and novel treatment strategies are being translated into powerful new treatment approaches in gynecologic cancers. A review in the most recent highlighted research that has deepened the understanding of the unique biology and molecular underpinnings of multiple gynecological cancers.
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
In 2009, New York initiated a policy to discourage breast cancer surgery at low-volume centers by denying payment for Medicaid patients. The intent was to improve outcomes across the state for lower-income patients by shifting their surgery to higher-volume centers.
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
A new ASCO guideline offers recommendations on the use of immunotherapy and targeted therapy for advanced gastroesophageal cancer. In a relatively short time, the treatment landscape for advanced gastroesophageal cancer has changed dramatically with the introduction of immunotherapy and other targeted agents, such as trastuzumab deruxtecan.
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Does AI Know and See All in Lung Cancer? - 8 month(s) ago
For
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Physicians lack knowledge and confidence when it comes to screening for breast cancer in transgender patients, according to research presented at the . Yanin Chavarri-Guerra, MD, of the Instituto Nacional de Ciencias Médicas y Nutrición in Mexico City, and colleagues surveyed 165 residents and fellows — about 58% were male, 40% were female, and 1% were non-binary.
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Mahdi Sheikh, MD, PhD, on Smoking and Kidney Cancer - 9 month(s) ago
Smokers newly diagnosed with kidney cancer may believe there’s no point in quitting, but recent evidence suggests otherwise. Mahdi Sheikh, MD, PhD, of the International Agency for Research on Cancer in Lyon, France, and colleagues prospectively followed 212 smokers with primary renal cell carcinoma for a median of 8 years.
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Jonathan Rosenberg, MD, on a Safe, Platinum-Free First-Line Combination in Advanced Bladder Cancer - 9 month(s) ago
About 50% of patients with locally advanced or metastatic urothelial carcinoma are not eligible for first-line treatment with standard-of-care combination cisplatin-based chemotherapy due to impaired renal function, poor performance status, and other comorbidities. In the limited number of patients treated with PD-1/PD-L1 inhibitors, outcomes remain poor, with a median overall survival of 10.4 months.
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Italian study looks at MDT challenges; Mara Antonoff, MD, on MDT, surgery, and stage III disease
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
What are the important issues and considerations when an individual receiving #gender-affirming #hormone therapy is diagnosed with a gendered #cancer? #oncology @ASCO #ASCOReadingRoom Read more: https://t.co/bCEsZDEQ8c https://t.co/estQAfV0Kb